Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/16/2026
- Dow hits record high as oil slides; SpaceX soars
- Oil prices fall 4% to three-month low on hopes interim US-Iran deal will reopen Hormuz
- Robinhood cuts 10% of staff as CEO Tenev pushes for 'lean' team
- Buy this sector after recent pullback, Morgan Stanley urges investors
- No "big top" yet in risk assets, BofA says despite elevated sentiment
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Brixmor Property Group announces passing of former CEO James Taylor
- SpaceX to acquire Cursor in $60 billion all-stock deal
- Wall Street rallies, Dow ends with record on US-Iran deal, oil price slide
- Wolfe Research sees substantial upside to AMD estimates
Edwards Lifesciences (EW) PT Raised to $125 at Leerink Partners
April 27, 2016 12:44 PM EDTLeerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted is price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $115.00) following continued strong results.
Antalffy commented, "Last night, EW reported yet another quarter of better than-expected sales -- now its 8th consecutive quarter of sales outperformance -- with 1Q16 adjusted sales of $695.6M (+18% y/y, +19% ex. FX), coming in ~$27M ahead of us and over $30M ahead of the Street. Again, stronger... More
Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
April 27, 2016 8:14 AM EDTPiper Jaffray analyst Brooks West raised his price target on Overweight-rated Edwards Lifesciences (NYSE: EW) to $123.00 (from $97.00) following another 'beat and raise' quarter.
West commented, "Edwards Lifesciences posted a strong beat-and-raise 1Q16 including revenue of $697.3M vs. consensus $664.2M (+20% y/y) and adjusted EPS of $0.71 vs. consensus... More
Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
April 26, 2016 4:21 PM EDTEdwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.71, $0.05 better than the analyst estimate of $0.66. Revenue for the quarter came in at $697.3 million versus the consensus estimate of $664.95 million.
"We are very pleased to report a strong start to 2016," said Michael A. Mussallem, chairman and CEO.... More
